Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 37.7% in October

Evogene Ltd. (NASDAQ:EVGN) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 98,200 shares, an increase of 37.7% from the September 30th total of 71,300 shares. Based on an average daily volume of 90,700 shares, the days-to-cover ratio is presently 1.1 days. Approximately 1.1% of the shares of the company are sold short. Approximately 1.1% of the shares of the company are sold short. Based on an average daily volume of 90,700 shares, the days-to-cover ratio is presently 1.1 days.

Analyst Upgrades and Downgrades

EVGN has been the topic of a number of recent analyst reports. Alliance Global Partners raised shares of Evogene to a “strong-buy” rating in a research report on Monday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $3.50.

Hedge Funds Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. Jane Street Group LLC grew its holdings in Evogene Ltd. (NASDAQ:EVGN) by 58.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,732 shares of the biotechnology company’s stock after buying an additional 12,387 shares during the quarter. Jane Street Group LLC owned 0.63% of Evogene worth $42,000 as of its most recent filing with the SEC. 10.40% of the stock is currently owned by institutional investors.

Evogene Stock Performance

Shares of EVGN stock traded down $0.04 during mid-day trading on Tuesday, reaching $1.22. The company’s stock had a trading volume of 49,750 shares, compared to its average volume of 681,088. Evogene has a 1-year low of $0.95 and a 1-year high of $2.42. The company has a market cap of $6.55 million, a P/E ratio of -0.54 and a beta of 1.56. The firm’s 50-day moving average is $1.24 and its two-hundred day moving average is $1.27.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.